{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:42:07Z","timestamp":1793212927938,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82374280"],"award-info":[{"award-number":["82374280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China Youth Science Foundation","award":["82104677"],"award-info":[{"award-number":["82104677"]}]},{"name":"Hospital capability enhancement project of Xiyuan Hospital, CACMS.","award":["XYZX0405-05"],"award-info":[{"award-number":["XYZX0405-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00867-6","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:02:37Z","timestamp":1738947757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Gaocan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"4","key":"867_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ccl.2017.07.002","volume":"35","author":"BD Hoit","year":"2017","unstructured":"Hoit BD. Anatomy and physiology of the Pericardium. Cardiol Clin. 2017;35(4):481\u201390.","journal-title":"Cardiol Clin"},{"issue":"6","key":"867_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cjca.2015.01.006","volume":"31","author":"WF McIntyre","year":"2015","unstructured":"McIntyre WF, Jassal DS, Morris AL. Pericardial effusions: do they all require pericardiocentesis? Can J Cardiol. 2015;31(6):812\u20135.","journal-title":"Can J Cardiol"},{"issue":"5","key":"867_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14779072.2022.2075346","volume":"20","author":"G Lazaros","year":"2022","unstructured":"Lazaros G, Lazarou E, Tsioufis P, Soulaidopoulos S, Iliakis P, Vlachopoulos C, et al. Chronic pericardial effusion: current concepts and emerging trends. Expert Rev Cardiovasc Ther. 2022;20(5):363\u201376.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"867_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11886-021-01539-7","volume":"23","author":"G Lazaros","year":"2021","unstructured":"Lazaros G, Vlachopoulos C, Lazarou E, Tsioufis K. New approaches to Management of Pericardial effusions. Curr Cardiol Rep. 2021;23(8):106.","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"867_CR5","first-page":"e9867","volume":"12","author":"NR Wilson","year":"2020","unstructured":"Wilson NR, Chauhan S, Aisenberg G. Hydralazine-Induced Lupus Syndrome Manifesting as large Pericardial Effusion. Cureus. 2020;12(8):e9867.","journal-title":"Cureus"},{"issue":"2","key":"867_CR6","first-page":"FD03","volume":"11","author":"S Wattal","year":"2017","unstructured":"Wattal S, Rao MS, Chandra GN, Razak UK, Shetty KR. Dasatinib Induced Cardiac Tamponade-A Rare Association. J Clin Diagn Res. 2017;11(2):FD03\u20134.","journal-title":"J Clin Diagn Res"},{"key":"867_CR7","doi-asserted-by":"publisher","first-page":"e2261","DOI":"10.1016\/j.ajem.2020.07.050","volume":"40","author":"M Oye","year":"2021","unstructured":"Oye M, Oye M, Ali A. Signs of early cardiac tamponade induced by Minoxidil. Am J Emerg Med. 2021;40:e2261\u20132.","journal-title":"Am J Emerg Med"},{"key":"867_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fped.2017.00079","volume":"5","author":"A P\u00e9rez-Casares","year":"2017","unstructured":"P\u00e9rez-Casares A, Cesar S, Brunet-Garcia L, Sanchez-de-Toledo J. Echocardiographic evaluation of Pericardial Effusion and Cardiac Tamponade. Front Pediatr. 2017;5:79.","journal-title":"Front Pediatr"},{"issue":"11","key":"867_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA adverse event reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19(11):1505\u201311.","journal-title":"Expert Opin Drug Saf"},{"key":"867_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2416933","volume":"17","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Li Z, Tao J, Yuan J, Fu Z. Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Expert Opin Drug Saf. 2024;17:1\u20138.","journal-title":"Expert Opin Drug Saf"},{"key":"867_CR11","doi-asserted-by":"publisher","first-page":"1417596","DOI":"10.3389\/fphar.2024.1417596","volume":"15","author":"M Fan","year":"2024","unstructured":"Fan M, Niu K, Wu X, Shi H. Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database. Front Pharmacol. 2024;15:1417596.","journal-title":"Front Pharmacol"},{"key":"867_CR12","doi-asserted-by":"publisher","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Chai S, Wang H, Dong J, Qin C, Du D, et al. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA adverse event reporting System database. Front Pharmacol. 2023;14:1259611.","journal-title":"Front Pharmacol"},{"issue":"3","key":"867_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4103\/apc.APC_16_20","volume":"13","author":"BB Das","year":"2020","unstructured":"Das BB, Dodson M, Guzman A. Recurrent pericarditis in an adolescent with Crohn\u2019s colitis. Ann Pediatr Cardiol. 2020;13(3):256\u20139.","journal-title":"Ann Pediatr Cardiol"},{"issue":"3","key":"867_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1179\/2295333715Y.0000000065","volume":"71","author":"D Kust","year":"2016","unstructured":"Kust D, Kruljac I, Peternac A\u0160, Ostoji\u0107 J, Prpi\u0107 M, \u010car\u017eavec D, et al. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism. Acta Clin Belg. 2016;71(3):175\u20137.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"867_CR15","doi-asserted-by":"publisher","first-page":"ytaa482","DOI":"10.1093\/ehjcr\/ytaa482","volume":"5","author":"P Shastri","year":"2020","unstructured":"Shastri P, Bhuta S, Oostra C, Monroe T. Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report. Eur Heart J Case Rep. 2020;5(1):ytaa482.","journal-title":"Eur Heart J Case Rep"},{"issue":"4","key":"867_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/qjmed\/hct223","volume":"107","author":"MA Chamsi-Pasha","year":"2014","unstructured":"Chamsi-Pasha MA, Bassiouny M, Kim ES. Hydralazine-induced lupus syndrome presenting with large pericardial effusion. QJM. 2014;107(4):305\u20137.","journal-title":"QJM"},{"issue":"7","key":"867_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"7","key":"867_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30(7):623\u20135.","journal-title":"Drug Saf"},{"issue":"30","key":"867_CR19","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"SJ Heo","year":"2020","unstructured":"Heo SJ, Jung I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat Med. 2020;39(30):4636\u201350.","journal-title":"Stat Med"},{"key":"867_CR20","doi-asserted-by":"publisher","first-page":"1480269","DOI":"10.3389\/fphar.2024.1480269","volume":"15","author":"XD Chen","year":"2024","unstructured":"Chen XD, Xiao KH, Zhou CB. Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004\u20132023). Front Pharmacol. 2024;15:1480269.","journal-title":"Front Pharmacol"},{"issue":"10","key":"867_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995\u20131006.","journal-title":"Drug Saf"},{"issue":"6","key":"867_CR22","doi-asserted-by":"publisher","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(6):e002771.","journal-title":"J Immunother Cancer"},{"key":"867_CR23","first-page":"15","volume":"65","author":"VV Kaushik","year":"2017","unstructured":"Kaushik VV. Review of Biosimilars of Adalimumab. J Assoc Physicians India. 2017;65:15\u201321.","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"867_CR24","first-page":"e34568","volume":"15","author":"S Lee","year":"2023","unstructured":"Lee S, Lafian A, Mahani T, Hojjati M. Adalimumab-Induced Lupus Serositis: a Case Report and Review of the literature. Cureus. 2023;15(2):e34568.","journal-title":"Cureus"},{"key":"867_CR25","doi-asserted-by":"publisher","first-page":"bcr2014207323","DOI":"10.1136\/bcr-2014-207323","volume":"2015","author":"D Kelly","year":"2015","unstructured":"Kelly D, O\u2019Connell O, Henry M. Adalimumab-induced lupus serositis. BMJ Case Rep. 2015;2015:bcr2014207323.","journal-title":"BMJ Case Rep"},{"key":"867_CR26","first-page":"985914","volume":"2013","author":"H Ozkan","year":"2013","unstructured":"Ozkan H, Cetinkaya AS, Yildiz T, Bozat T. A rare side effect due to TNF-Alpha blocking Agent: Acute Pleuropericarditis with Adalimumab. Case Rep Rheumatol. 2013;2013:985914.","journal-title":"Case Rep Rheumatol"},{"key":"867_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"key":"867_CR28","doi-asserted-by":"publisher","first-page":"107815522311719","DOI":"10.1177\/10781552231171925","volume":"25","author":"G Johnson","year":"2023","unstructured":"Johnson G, Baviriseaty N, Massanet N, Kooper J. Serositis causing pericardial and pleural effusions after eight years of maintenance ibrutinib for Waldenstrom\u2019s macroglobulinemia. J Oncol Pharm Pract. 2023;25:10781552231171925.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"867_CR29","first-page":"1645","volume":"205","author":"B Fakhri","year":"2024","unstructured":"Fakhri B, Wang V, Perez-Burbano G, Wall A, Mandrekar S, Parikh SA, Woyach J, Shanafelt T. Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials. Br J Haematol. 2024;205(4):1645\u20138.","journal-title":"Br J Haematol"},{"issue":"9","key":"867_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/14740338.2023.2204226","volume":"22","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Hu F, Shi W, Ye X, Xu J, Guo X, et al. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors. Expert Opin Drug Saf. 2023;22(9):857\u201369.","journal-title":"Expert Opin Drug Saf"},{"key":"867_CR31","first-page":"4282486","volume":"2020","author":"JL Miatech","year":"2020","unstructured":"Miatech JL, Hughes JH, McCarty DK, Stagg MP. Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy. Case Rep Hematol. 2020;2020:4282486.","journal-title":"Case Rep Hematol"},{"issue":"12","key":"867_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jaccas.2022.01.027","volume":"4","author":"H Jeelani","year":"2022","unstructured":"Jeelani H, Sheikh MM, Tahir N, Ying G, Prasad S, Yaremko M, et al. Left atrial appendage occlusion as an alternative to anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion. JACC Case Rep. 2022;4(12):751\u20134.","journal-title":"JACC Case Rep"},{"issue":"4","key":"867_CR33","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1177\/10781552211073885","volume":"28","author":"B Aslan Cand\u0131r","year":"2022","unstructured":"Aslan Cand\u0131r B, Yi\u011feno\u011flu TN, K\u0131z\u0131l \u00c7akar M, Dal MS, Altunta\u015f F. Non hemorrhagic pericardial effusion from ibrutinib in a patient without comorbidities. J Oncol Pharm Pract. 2022;28(4):972\u20134.","journal-title":"J Oncol Pharm Pract"},{"key":"867_CR34","doi-asserted-by":"publisher","first-page":"1443555","DOI":"10.3389\/fphar.2024.1443555","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Liu C, Zhang Z, Cai Z, Lv T, Zhang R, et al. Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1443555.","journal-title":"Front Pharmacol"},{"issue":"10","key":"867_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17425255.2022.2129005","volume":"18","author":"A Shahzad Qamar","year":"2022","unstructured":"Shahzad Qamar A, Zamir A, Khalid S, Ashraf W, Imran I, Hussain I, et al. A review on the clinical pharmacokinetics of hydralazine. Expert Opin Drug Metab Toxicol. 2022;18(10):707\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"867_CR36","first-page":"e9831","volume":"12","author":"KO Elkholy","year":"2020","unstructured":"Elkholy KO, Akhtar H, Chakraborti A. A case of Seronegative ANA Hydralazine-Induced Lupus presenting with Pericardial Effusion and Pleural Effusion. Cureus. 2020;12(8):e9831.","journal-title":"Cureus"},{"key":"867_CR37","doi-asserted-by":"publisher","first-page":"3521541","DOI":"10.1155\/2017\/3521541","volume":"2017","author":"V Zeitjian","year":"2017","unstructured":"Zeitjian V, Mehdizadeh A. ANA-Negative Hydralazine-Induced Pericardial Effusion. Case Rep Med. 2017;2017:3521541.","journal-title":"Case Rep Med"},{"issue":"3","key":"867_CR38","first-page":"377","volume":"32","author":"MF Rahman","year":"2019","unstructured":"Rahman MF, Panezai MA, Szerlip HM. Hydralazine-induced pericardial effusion. Proc (Bayl Univ Med Cent). 2019;32(3):377\u20138.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"5","key":"867_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","volume":"30","author":"Y He","year":"2018","unstructured":"He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"867_CR40","first-page":"5245904","volume":"2017","author":"P Iyer","year":"2017","unstructured":"Iyer P, Dirweesh A, Zijoo R. Hydralazine Induced Lupus Syndrome presenting with recurrent Pericardial Effusion and a negative antinuclear antibody. Case Rep Rheumatol. 2017;2017:5245904.","journal-title":"Case Rep Rheumatol"},{"issue":"4","key":"867_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.5152\/eurjrheum.2018.18040","volume":"5","author":"T Solomon-Tsegaye","year":"2018","unstructured":"Solomon-Tsegaye T, Treadwell EL, Obi R, Pitzalis M. Antinuclear antibody-negative lupus? An ominous presentation of hydralazine-induced lupus syndrome. Eur J Rheumatol. 2018;5(4):272\u20134.","journal-title":"Eur J Rheumatol"},{"issue":"2\u20133","key":"867_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.14712\/23362936.2019.10","volume":"120","author":"J Ho\u0159\u00ednkov\u00e1","year":"2019","unstructured":"Ho\u0159\u00ednkov\u00e1 J, \u0160\u00edma M, Slana\u0159 O. Pharmacokinetics of Dasatinib. Prague Med Rep. 2019;120(2\u20133):52\u201363.","journal-title":"Prague Med Rep"},{"issue":"7","key":"867_CR43","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","volume":"59","author":"D Lev\u00eaque","year":"2020","unstructured":"Lev\u00eaque D, Becker G, Bilger K, Natarajan-Am\u00e9 S. Clinical pharmacokinetics and pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020;59(7):849\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"867_CR44","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/j.clml.2021.01.020","volume":"21","author":"H Shin","year":"2021","unstructured":"Shin H, Ha JE, Zang DY, Kim SH, Do YR, Lee WS, et al. Appropriate starting dose of Dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(6):e521\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"867_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.21037\/tp-23-517","volume":"13","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wang K, Yu L, Guo Y, Li Z. Dasatinib-induced pleural effusions, pericardial effusion and pulmonary arterial hypertension: a case report. Transl Pediatr. 2024;13(4):673\u201381.","journal-title":"Transl Pediatr"},{"issue":"1","key":"867_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2010.030494","volume":"96","author":"MT Krauth","year":"2011","unstructured":"Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schl\u00f6gl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100\u00a0mg or 50\u00a0mg daily. Haematologica. 2011;96(1):163\u20136.","journal-title":"Haematologica"},{"key":"867_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejpb.2021.07.014","volume":"167","author":"PM Veloso","year":"2021","unstructured":"Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - from well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm. 2021;167:89\u2013103.","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"867_CR48","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1517\/14656566.2013.808622","volume":"14","author":"V Criscuoli","year":"2013","unstructured":"Criscuoli V, Modesto I, Orlando A, Cottone M. Mesalazine for the treatment of inflammatory bowel disease. Expert Opin Pharmacother. 2013;14(12):1669\u201378.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"867_CR49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0167-5273(98)00367-2","volume":"68","author":"F Vayre","year":"1999","unstructured":"Vayre F, Vayre-Oundjian L, Monsuez JJ. Pericarditis associated with longstanding mesalazine administration in a patient. Int J Cardiol. 1999;68(2):243\u20135.","journal-title":"Int J Cardiol"},{"issue":"1","key":"867_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13256-017-1557-z","volume":"12","author":"ST Radhakrishnan","year":"2018","unstructured":"Radhakrishnan ST, Mohanaruban A, Hoque S. Mesalazine-induced myocarditis: a case report. J Med Case Rep. 2018;12(1):44.","journal-title":"J Med Case Rep"},{"issue":"10","key":"867_CR51","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.gastrohep.2020.10.003","volume":"44","author":"A Ezquerra","year":"2021","unstructured":"Ezquerra A, Resina E, Montes \u00c1, \u00c1lvarez-Mal\u00e9 T, Gisbert P. Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis. Gastroenterol Hepatol. 2021;44(10):721\u20133.","journal-title":"Gastroenterol Hepatol"},{"issue":"8","key":"867_CR52","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s10620-013-2566-4","volume":"58","author":"I Sonu","year":"2013","unstructured":"Sonu I, Wong R, Rothenberg ME. 5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis. Dig Dis Sci. 2013;58(8):2148\u201350.","journal-title":"Dig Dis Sci"},{"key":"867_CR53","doi-asserted-by":"publisher","first-page":"970597","DOI":"10.3389\/fphar.2022.970597","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Duan T, Fang W, Liu S, Wang C. Analysis of clinical characteristics of mesalazine-induced cardiotoxicity. Front Pharmacol. 2022;13:970597.","journal-title":"Front Pharmacol"},{"issue":"7","key":"867_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/13696998.2017.1302947","volume":"20","author":"J Lin","year":"2017","unstructured":"Lin J, Makenbaeva D, Lingohr-Smith M, Bilmes R. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors. J Med Econ. 2017;20(7):687\u201391.","journal-title":"J Med Econ"},{"issue":"1","key":"867_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000375484","volume":"8","author":"V Agrawal","year":"2015","unstructured":"Agrawal V, Christenson ES, Showel MM. Tyrosine kinase inhibitor induced isolated pericardial effusion. Case Rep Oncol. 2015;8(1):88\u201393.","journal-title":"Case Rep Oncol"},{"issue":"7","key":"867_CR56","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2217\/imt-2021-0223","volume":"14","author":"H Li","year":"2022","unstructured":"Li H, Han D, Zhang L, Feng X, Li H, Yang F, et al. PD-1\/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. Immunotherapy. 2022;14(7):577\u201392.","journal-title":"Immunotherapy"},{"issue":"1","key":"867_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","volume":"7","author":"A Saade","year":"2019","unstructured":"Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F, Oudard S, Weiss L. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7(1):266.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"867_CR58","doi-asserted-by":"publisher","first-page":"e00404","DOI":"10.1002\/rcr2.404","volume":"7","author":"M Tachihara","year":"2019","unstructured":"Tachihara M, Yamamoto M, Yumura M, Yoshizaki A, Kobayashi K, Nishimura Y. Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade. Respirol Case Rep. 2019;7(3):e00404.","journal-title":"Respirol Case Rep"},{"key":"867_CR59","doi-asserted-by":"publisher","first-page":"132029","DOI":"10.1016\/j.ijcard.2024.132029","volume":"407","author":"M Tang","year":"2024","unstructured":"Tang M, Dang P, Liu T, Yang K, Wang Y, Tse G, et al. Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors. Int J Cardiol. 2024;407:132029.","journal-title":"Int J Cardiol"},{"issue":"1","key":"867_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1346-8138.13497","volume":"44","author":"Y Hamaguchi","year":"2017","unstructured":"Hamaguchi Y, Sumida T, Kawaguchi Y, Ihn H, Tanaka S, Asano Y, et al. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: prospective, multicenter, open-label study. J Dermatol. 2017;44(1):13\u20137.","journal-title":"J Dermatol"},{"issue":"10","key":"867_CR61","first-page":"e30021","volume":"14","author":"SA Nasir","year":"2022","unstructured":"Nasir SA, Babu Pokhrel N, Baig A. Hemorrhagic Pericardial Effusion from Apixaban Use: Case Report and Literature Review. Cureus. 2022;14(10):e30021.","journal-title":"Cureus"},{"issue":"4","key":"867_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.14740\/cr902","volume":"10","author":"M Cinelli","year":"2019","unstructured":"Cinelli M, Uddin A, Duka I, Soomro A, Tamburrino F, Ghavami F, et al. Spontaneous hemorrhagic Pericardial and Pleural Effusion in a patient receiving apixaban. Cardiol Res. 2019;10(4):249\u201352.","journal-title":"Cardiol Res"},{"key":"867_CR63","doi-asserted-by":"publisher","first-page":"e944173","DOI":"10.12659\/AJCR.944173","volume":"25","author":"R Latif","year":"2024","unstructured":"Latif R, Aloqaily M, Rabadi A, Arshad K, Kurian AI, Obeidat I, et al. Apixaban-Induced Hemopericardium in a Post-TAVR patient: a Case Report highlighting Diagnostic and Management challenges. Am J Case Rep. 2024;25:e944173.","journal-title":"Am J Case Rep"},{"issue":"5","key":"867_CR64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.acvd.2013.02.003","volume":"106","author":"M Andrejak","year":"2013","unstructured":"Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis. 2013;106(5):333\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"9689","key":"867_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","volume":"374","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet. 2009;374(9689):577\u201385.","journal-title":"Lancet"},{"issue":"11","key":"867_CR66","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.3390\/ijms21114003","volume":"21","author":"C Oury","year":"2020","unstructured":"Oury C, Mar\u00e9chal P, Donis N, Hulin A, Hego A, Tridetti J, et al. Dexfenfluramine and Pergolide cause Heart Valve Disease via Valve metabolic reprogramming and Ongoing Matrix Remodeling. Int J Mol Sci. 2020;21(11):4003.","journal-title":"Int J Mol Sci"},{"issue":"5\u20136","key":"867_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/08820538.2013.849271","volume":"30","author":"W Andreatta","year":"2015","unstructured":"Andreatta W, Shah P. Reversible hypotony and Choroidal Effusion following the Use of Pergolide for Parkinson\u2019s Disease. Semin Ophthalmol. 2015;30(5\u20136):423\u20135.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"867_CR68","first-page":"e54491","volume":"16","author":"U Khizer","year":"2024","unstructured":"Khizer U, Annam B, Akhtar A, Dhaliwal JS, Yang C. Fatal differentiation syndrome complicating Acute promyelocytic leukemia treatment: a Case Report. Cureus. 2024;16(2):e54491.","journal-title":"Cureus"},{"key":"867_CR69","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.jaccas.2023.102043","volume":"25","author":"M Atar","year":"2023","unstructured":"Atar M, Majid M, Yaker Z, Agrawal A, Arockiam AD, Gerds AT, et al. Successful treatment of recurrent Pericarditis with Rilonacept in Acute promyelocytic leukemia. JACC Case Rep. 2023;25:102043.","journal-title":"JACC Case Rep"},{"issue":"1","key":"867_CR70","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.leukres.2009.08.016","volume":"34","author":"K Ueda","year":"2010","unstructured":"Ueda K, Nagai S, Miyashita SI, Kaise T, Ichikawa M, Kumano K, et al. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome. Leuk Res. 2010;34(1):e25\u20136.","journal-title":"Leuk Res"},{"issue":"2","key":"867_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12012-018-09504-7","volume":"19","author":"VP Vineetha","year":"2019","unstructured":"Vineetha VP, Raghu KG. An overview on Arsenic Trioxide-Induced Cardiotoxicity. Cardiovasc Toxicol. 2019r;19(2):105\u201319.","journal-title":"Cardiovasc Toxicol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00867-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:02:45Z","timestamp":1738947765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00867-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00867-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data for this study was directly obtained from publicly available information in the US Food and Drug Administration Adverse Event Reporting System (FAERS), and therefore does not require ethics committee approval, nor does it involve the issue of participant consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}